Novavax (NVAX) said Wednesday it believes its biologics license application for its COVID-19 vaccine is "approvable" by the US Food and Drug Administration based on ongoing discussions.
The company said the FDA recently asked for a post-marketing commitment to collect additional clinical data.
Novavax said it will work quickly to comply with the request and obtain final approval.
Shares of Novavax rose 12% in recent premarket activity Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。